Sepsis Diagnostics Market 2019: Global Size, Growth Factors, Top Leaders, Opportunities, Emerging Technologies and Regional Forecast to 2022

May 3, 2019

An expert on premium research reports, Market Research Future has added a report titled "Global Sepsis Diagnostics Market 2022" to its offering.

Pune, India - May 3, 2019 /MarketersMedia/ —

Market Scenario:

The severity of the symptoms of sepsis necessitate the availability of accurate tests that can detect the ailment at the initial stages. The sepsis diagnostic market is expected to be motivated by the escalating level of investments from industry players. The enhanced collection of patient outcome information and incorporation into medical records is anticipated to additionally inspire the expansion of the sepsis diagnostic market in the forecast period.

The development of diagnostic tools for a diverse range of ailments has facilitated the development of the sepsis diagnostic market as well. Market reports connected with healthcare industry have been offered by Market Research Future which creates reports on other industry verticals that intends to analyze the current market scenarios better.

The market is on track to attain an 8% CAGR while earning USD 710 million in the forecast period.

Get Free Sample Copy @ https://www.marketresearchfuture.com/sample_request/2110

There is a necessity for new sepsis biomarkers that can assistance in therapeutic decision making and adds information about diagnosis, screening, risk stratification, and monitoring of the response to therapy. The host patient’s response includes hundreds of mediators and single molecules, many of which have been projected as biomarkers. It is, nevertheless, unlikely that one single biomarker is capable to fulfil all the needs and potentials for sepsis research, development and management. Among biomarkers that are assessable by assays approved for clinical use, procalcitonin (PCT) has shown some effectiveness as an infection marker and for antibiotic stewardship. Other potential new methodologies consist of molecular strategies to develop pathogen detection and molecular diagnostics and prognostics based on transcriptomic, proteomic, or metabolic profiling. Novel methodologies for sepsis promise to alter sepsis from a physiologic syndrome into a group of distinct biochemical condition and help in the improvement of better diagnostic tools and effective adjunctive sepsis therapies.

Competitive Analysis

The prominent competitors in the sepsis diagnostic market are EKF Diagnostics (UK), T2 Biosystems, Inc. (US), bioMérieux, Inc. (US), Becton, Dickinson and Company (US), Sandstone Diagnostics, Inc. (US), Immunexpress (US), Axis-Shield Diagnostics Ltd. (Scotland), Cube Dx GmbH (Austria), and others.

Segmental Analysis

The segmental analysis of the sepsis diagnostics market has been carried out on the basis of technology, product type, end-user, and region. Based on technology, the sepsis diagnostic market consists of biomarkers, molecular diagnostics, immunoassays, and others. By type of products, the sepsis market is segmented into instruments, kits, blood culture media, and others. Based on end users, the sepsis diagnostic market is segmented into specialty clinics, hospitals, pathology laboratories, diagnostic centers, and others. The regions that are considered in the sepsis diagnostic market are the Americas, Europe, Asia Pacific, Middle East, and Africa.

Industry Updates:

Dec 2018 Beckman Coulter, which is an international leader in the clinical diagnostics industry has announced that it is joining forces with Sepsis Alliance, the nation's leading sepsis organization, to support the Sepsis Coordinator Network. The pioneering online, peer-to-peer alliance for healthcare professionals, the Sepsis Coordinator Network is dedicated to saving lives by advancing patient results.

May 2018 Mobidiag, a Finnish firm, has obtained funding to creäte a rapid molecular sepsis assay on its Novodiag system. The fresh funding comprises of a €1.5 million ($1.74 million) loan for the first year of the project provided by Business Finland, a funding agency previously known as Tekes.

Detailed Regional Analysis

The region-based study of the sepsis diagnostic market includes regions such as Americas, Europe, Asia Pacific, Middle East, and Africa. The North American region is the major market for medical tourism which is expected to motivate the development of the sepsis market in the forecast period. The North American market for sepsis diagnostics is anticipated to achieve USD 320 million by the end of the forecasted period. The European region is the next prime market for sepsis diagnostics which is anticipated to develop at the CAGR of 6.8%. While the Asia Pacific region is anticipated to be the most rapidly growing region in sepsis diagnostics market.

        

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Info:
Name: Market Research Future
Email: Send Email
Organization: Market Research Future
Address: Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar, Pune - 411028 Maharashtra, India
Phone: +1 646 845 9312
Website: https://www.marketresearchfuture.com

Source URL: https://marketersmedia.com/sepsis-diagnostics-market-2019-global-size-growth-factors-top-leaders-opportunities-emerging-technologies-and-regional-forecast-to-2022/508776

Source: MarketersMedia

Release ID: 508776

More News

PH pharma firm marks 80 years with new health, wellness offerings 

Sep 15, 2026

PH pharma firm marks 80 years with new health, wellness offerings 

Pascual Laboratories, Inc. is marking its 80th year in the Philippines with new health and wellness offerings and campaigns for several of its established brands. Founded in 1946 by Isosceles and Leonora Pascual, the company began by addressing what it described as the post-war health needs of fellow Filipinos. Eight decades later, it continues to expand its portfolio while commemorating the milestone under the theme “#GalingThatKeepsGoing.” Among the new offerings introduced this year are Alevia-B, which marks the company’s entry into the mobility market, and MyColla C, a food supplement combining marine collagen and vitamin C. Alevia-B combines paracetamol with vitamins B1 (thiamine), B6 (pyridoxine) and B12 (cyanocobalamin) in a single tablet. According to the company, the formulation is intended to help relieve mild to moderate muscle, joint or nerve-related pain while supporting normal nerve function. Paracetamol is a widely used first-line non-opioid analgesic for mild to moderate pain. Vitamins B1, B6 and B12 are essential for normal nervous system function and contribute to neuronal metabolism and myelin maintenance. The company said the formulation brings together an analgesic component with neurotropic vitamins, offering a complementary approach to addressing different components of pain. The other new product, MyColla C, combines premium hydrolyzed marine collagen with vitamin C. The company said the collagen provides building blocks that help support skin health, including elasticity, hydration and firmness, while vitamin C is essential in producing and maintaining collagen. The combination supports normal collagen formation and structure when paired with proper diet and exercise. MyColla C is available in three formats: Strawberry Milk powdered drink sachets, unflavored sachets that can be mixed with drinks and chewable tablets. The anniversary year also includes new campaigns for several of the company’s flagship brands. Poten-Cee Vitamin C launched its “#CeeGe Lang” campaign, while Ascof Forte introduced a campaign focused on natural cough relief for various coughs not caused by bacterial infection. C-Lium Fibre unveiled its “#PowerTheSlay” campaign earlier this year, focusing on irregular bowel movement. Poten-Cee + C also highlights the combination of bovine and marine collagen through its “#MyGlowToChoice” campaign. As part of its 80th-anniversary activities, PascualLab also offered customers P80 Mercury Drug gift certificates for every accumulated purchase of P400 worth of PascualLab products. The company said more offerings are in the pipeline as it continues its anniversary year. From its beginnings in 1946, PascualLab has expanded its health and wellness portfolio to include products such as OraCare Mouthrinse, PelarGo and Glutaphos. Its 80th anniversary looks back on that history while emphasizing the company’s continuing efforts to address the health needs of Filipinos.

YOUR NEWS, OUR NETWORK.

Do you have Great News you want to tell the world?

Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.